Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?

Title: Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?

Volume: 12 Issue: 33

Author(s): Chewki Ziani-Cherif, Bachir Mostefa-Kara and Fatima Z. Brixi-Gormat

Affiliation:

Keywords: Alzheimer disease, amyloid βprecursor protein, amyloid β, γ-secretase, presenilins, γ-secretase inhibitors, nonsteroidal anti-inflammatory drugs

Abstract: Alzheimer disease (AD) is characterized by excessive deposition of amyloid β-peptides (Aβ peptides) in the form of senile plaques as well as neurofibrillary tangles (NFTs) in the brain. In the amyloidogenic pathway, the amyloid-β precursor protein (APP) is cleaved by β-secretase first, followed by γ-secretase cleavage producing therefore Aβ. This review summarizes the recent findings in the AD field and focuses on the different γ-secretase inhibitors that have been developed as a therapeutic approach toward AD.

Cite this article as:

Ziani-Cherif Chewki, Mostefa-Kara Bachir and Brixi-Gormat Z. Fatima, Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?, Current Pharmaceutical Design 2006; 12 (33) . https://dx.doi.org/10.2174/138161206778792994